Results 21 to 30 of about 25,773 (228)

A Randomized, Double-Blind, Placebo-Controlled Study of the PD-1 Inhibitor Cetrelimab in Chronic Hepatitis B. [PDF]

open access: yesJ Viral Hepat
ABSTRACT Hepatitis B virus (HBV)‐induced T‐cell exhaustion may be reversed using a programmed death receptor 1 (PD‐1) inhibitor such as cetrelimab, an investigational fully human monoclonal antibody targeting PD‐1. To evaluate the safety, activity and pharmacokinetics of low‐dose (i.e., a dose lower than that used in oncology) cetrelimab in ...
Asselah T   +10 more
europepmc   +2 more sources

CHRONIC HEPATITIS B VIRUS INFECTION IN PREGNANCY: STRATEGIES OF ANTIVIRAL THERAPY

open access: yesAlʹmanah Kliničeskoj Mediciny, 2016
Treatment of chronic hepatitis B during pregnancy is an extremely complicated issue. Despite  implementation of immune prophylaxis, a significant proportion of babies born by mothers with  high viral load are infected by hepatitis B virus.
P. O. Bogomolov   +5 more
doaj   +1 more source

Radioimmunoassay of Hepatitis B e-antigen (HBeAg): identification of HBeAg not associated with Immunoglobulins

open access: yesJournal of General Virology, 1979
A radioimmunoassay for hepatitis B e-antigen (HBeAg) is described. Polystyrene beads coated with IgG prepared from a human serum containing antibodies to HBeAg (anti-HBe) and anti-HBe IgG labelled with 125I-p-hydroxyphenylpropionic acid N-hydroxysuccinimide ester were used in the test.
A R, Neurath   +4 more
openaire   +2 more sources

PROPORTION OF HBsAg AND HBeAg POSITIVE IN MATERNAL PATIENTS AND THEIR HBsAg POSITIVES BABIES WITH IMMUNOPROPHYLAXIS OF HBV IMMUNIZATION IN Dr. SOETOMO GENERAL HOSPITAL, SURABAYA

open access: yesIndonesian Journal of Tropical and Infectious Disease, 2017
Hepatitis B Virus (HBV) can be transmitted vertically from mother to her baby. Mothers with HBsAg and HBeAg positives have more risk of transmitting HBV to her baby rather than HBsAg positives only. The aim of this study is to determine the proportion of
Melina Rosita Tanadi   +2 more
doaj   +1 more source

Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy

open access: yesScientific Reports, 2021
Tenofovir and entecavir are currently designated as the preferred oral antiviral drugs for chronic hepatitis B. However, only less than 40% of patients can achieve HBeAg seroconversion.
Yu-Li Zeng   +15 more
doaj   +1 more source

Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection

open access: yesEmerging Microbes and Infections, 2021
Hepatitis B e antigen (HBeAg) is a widely used marker both for chronic hepatitis B (CHB) clinical management and HBV-related basic research. However, due to its high amino acid sequence homology to hepatitis B core antigen (HBcAg), most of available anti-
Shao-Juan Wang   +17 more
doaj   +1 more source

The prevalence of hepatitis B virus E antigen among Ghanaian blood donors

open access: yesThe Pan African Medical Journal, 2014
Hepatitis B viral infection is an important clinical problem due to its worldwide distribution and potential of adverse sequelae, including hepatocellular carcinoma (HCC). We studied the prevalence of hepatitis B virus e antigen (HBeAg) among individuals
Tanko Rufai   +3 more
doaj   +1 more source

Serological Markers Hbsag and Hbeag in Chronic Hepatitis B Carriers and their Correlation with Viral DNA by Polymerase Chain Reaction

open access: yesJournal of Pure and Applied Microbiology, 2019
Hepatitis B is the most widespread and important type of viral hepatitis which may become chronic and lead to complications like cirrhosis and hepatocellular carcinoma.
Rasika Borgaonkar, Praveen R. Shahapur
doaj   +1 more source

Efficacy and clinical outcomes of different antiviral regimens in HBeAg/HBeAb double-positive patients with chronic hepatitis B

open access: yesDi-san junyi daxue xuebao, 2022
Objective To analyze the clinical features of HBeAg and HBeAb double-positive patients with chronic hepatitis B, and explore the efficacy and outcomes of different antiviral regimens.
AN Xuan   +6 more
doaj   +1 more source

Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance

open access: yesBMC Gastroenterology, 2020
Background Hepatitis B e antigen (HBeAg) seroclearance has been considered as the treatment endpoint in HBeAg-positive patients with chronic hepatitis B (CHB). Although HBeAg seroclearance has been accomplished, some aspects are yet unclear.
Hyun Woong Lee   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy